Super Micro Computer Stock Jumps 20% After Record AI Orders and Margin Surge 
Houthi Naval Blockade on Saudi Arabia Escalates Iran Conflict, Threatens Global Oil Supply 
US Dollar Holds Near One-Week High as Middle East Tensions and Oil Prices Drive Market Sentiment 
Oil Prices Extend Four-Day Rally as U.S.-Iran Conflict and Red Sea Threats Raise Supply Fears 
GM Q2 Earnings Beat Estimates as General Motors Raises 2026 Profit Outlook 
Judge Approves Anthropic’s $1.5 Billion AI Copyright Settlement With Authors 
Asian Currencies Hold Steady as Middle East Tensions Boost US Dollar, Oil Concerns 
IBM Q2 Earnings Miss Estimates as Software Growth Offsets Infrastructure Weakness 
US-Iran Conflict Escalates as Gulf Attacks Threaten Global Oil Supply 
Macquarie Names Greg Ward as CEO, Signaling Stability and Strategic Continuity 
OpenAI Australia Data Center Switches Cooling Strategy After Recycled Water Plan Fails 
Samsung Cuts U.S. Consumer Electronics Jobs as Headquarters Moves to Texas 
Cathay Pacific Sees H1 Profit Surge on Strong Travel Demand 
Gold Price Jumps Near 2% Above $4,080 as Middle East Tensions Lift Safe-Haven Demand 
Gold Price Surges Above $4,100 as Middle East Tensions Boost Safe-Haven Demand 
Alaska Air Q3 Outlook Misses Estimates as Higher Fuel Costs Weigh on Profit Forecast 
European Stocks Slip as Earnings, UK Inflation and ECB Decision Keep Investors on Edge 
Samsung Biologics is now confirmed to produce Moderna’s COVID-19 vaccines in South Korea. The biotechnology company headquartered in Incheon is said to be working to hasten preparations and begin the production of the shots in the second half of this year.
Confirmation of the vaccine production deal
The Korea Herald reported that Samsung Biologics is preparing its drug manufacturing facility in Songdo, Incheon. This is said to be one of the largest in the world and it is here where the biotech firm will be handling the filling and finishing process of Moderna vaccine production. To be more specific, the mRNA-1273 which is the American pharmaceutical company’s messenger-RNA-based COVID-19 shot.
The Samsung and Moderna agreement was officially signed and this was witnessed by South Korean President Moon Jae In looking. The deal is actually part of the Korean-US vaccine partnership that was one of the agendas at the recent summit that was held in the U.S. last week.
The agreement between Samsung Biologics and Moderna
Samsung Biologics will be filling up vials and packaging them for sale and distribution. The main vaccine content will be coming directly from Moderna and Lonza, its Swiss production partner, and the overall finishing process will be done in Korea.
"This vaccine is paramount to people around the world in the fight against the COVID-19 pandemic, and we truly appreciate our client Moderna for entrusting and choosing to partner with Samsung Biologics for the fill and finish of this important vaccine," Samsung Biologics CEO, John Rim, said in a press release."Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021."
On the other hand, Moderna’s chief technical operations and quality officer, Juan Andres, said that they are pleased to team up with Samsung Biologics for the fill and finish production. He explained that this arrangement will help them continue to boost their manufacturing capacity outside of the U.S. as they remained committed to beating COVID-19.
Meanwhile, South Korean government officials gladly welcomed the partnership as this is a big opportunity for the country to scale up and be a global factory of vaccines for COVID-19.
